GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Foundation Medicine Inc (NAS:FMI) » Definitions » Net Income

Foundation Medicine (Foundation Medicine) Net Income : $-141.5 Mil (TTM As of Jun. 2018)


View and export this data going back to 2013. Start your Free Trial

What is Foundation Medicine Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Foundation Medicine's Net Income for the three months ended in Jun. 2018 was $-33.4 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2018 was $-141.5 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Foundation Medicine's Earnings per Share (Diluted) for the three months ended in Jun. 2018 was $-0.90.


Foundation Medicine Net Income Historical Data

The historical data trend for Foundation Medicine's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foundation Medicine Net Income Chart

Foundation Medicine Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Net Income
Get a 7-Day Free Trial -42.94 -52.22 -89.63 -113.19 -161.47

Foundation Medicine Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.26 -32.64 -38.11 -37.42 -33.38

Foundation Medicine Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Foundation Medicine's Net Income for the fiscal year that ended in Dec. 2017 is calculated as

Net Income(A: Dec. 2017 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-161.466+0+0+0
=-161.5

Foundation Medicine's Net Income for the quarter that ended in Jun. 2018 is calculated as

Net Income(Q: Jun. 2018 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-33.379+0+0+0
=-33.4

Net Income for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-141.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Foundation Medicine  (NAS:FMI) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Foundation Medicine's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2018 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Foundation Medicine Net Income Related Terms

Thank you for viewing the detailed overview of Foundation Medicine's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Foundation Medicine (Foundation Medicine) Business Description

Traded in Other Exchanges
N/A
Address
Foundation Medicine Inc is a molecular diagnostics company that specializes in the evaluation and treatment of cancer. Its products provide genetic information about a patient's cancer that is used by physicians to inform clinical decisions and by biopharmaceutical companies to develop targeted oncology therapies. Foundation Medicine's core molecular information products include FoundationOne, for solid tumors, and FoundationOne Heme, for blood-based cancers and hematologic malignancies. The vast majority of the firm's revenue is generated within the United States.
Executives
Alexis Borisy director C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 16TH FLOOR, CAMBRIDGE MA 02142
Vincent A. Miller officer: Chief Medical Officer C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Michael J Pellini director 222 DUTTON MILL RD, WILLISTOWN PA 19380
Jason Ryan officer: Chief Financial Officer C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Troy Cox director, officer: President and CEO C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141
Robert W. Hesslein officer: SVP and General Counsel C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas Civik officer: Chief Commercial Officer C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Evan/ Fa Jones director C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Roche Finance Ltd director, 10 percent owner, other: See footnote (1) C/O HOFFMAN LA ROCHE, 124 GRENSACHERSTRASSE CH 4002, BASEL SWITZERLAND V8
Roche Holding Ltd director, 10 percent owner, other: See footnote (1) ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
David P Schenkein director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Robert I Tepper 10 percent owner 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Mark J Levin 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Third Rock Ventures Gp, L.p. 10 percent owner C/O THIRD ROCK VENTURES, 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116